Hemolytic disease of the fetus and newborn and Rhesus alloimmunization in Latin American countries: a scoping review

被引：0
作者：
Correa Junior, Mario Dias [1 ]
Espino y Sosa, Salvador [2 ]
Fernandes, Milene [3 ]
do Carmo, Lais [4 ]
de Oliveira, Renato Watanabe [5 ]
Kanevsky, Gabriela [6 ]
机构：
[1] Minas Gerais Fed Univ, Dept Obstet & Gynecol, Campus Hlth,Ave Prof Alfredo Balena 190 Santa Efig, BR-30130100 Belo Horizonte, MG, Brazil
[2] Inst Nacl Perinatol Isidro Espinosa de Reyes, Clin Res Dept, Mexico City, Mexico
[3] CTI Clin Trial & Consulting Serv, RWE & Late Phase, Lisbon, Portugal
[4] Janssen Cilag, HEOR LATAM, Sao Paulo, Brazil
[5] Janssen Cilag, RWE LATAM, Sao Paulo, Brazil
[6] Janssen, Immunol LATAM, RA-1428 Mendoza, Buenos Aires, Argentina
来源：
BMC PREGNANCY AND CHILDBIRTH | 2024年 / 24卷 / 01期
关键词：
Infant; Newborn; Anemia; Hemolytic; Rh alloimmunization; Erythroblastosis; Fetal; Latin America;
D O I：
10.1186/s12884-024-07044-3
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
BackgroundHemolytic disease of the fetus and newborn (HDFN) is a condition due to maternal blood group antibodies targeting antigens in fetal red blood cells, with significant prenatal/perinatal morbidity and mortality. Severe HDFN cases are often associated with alloimmunization against Rhesus D (RhD) or Kell antigens. Information about HDFN epidemiology and treatment in Latin American countries is limited. This review aims to identify and synthesize the available evidence on the epidemiology and management of HDFN in this region.MethodsIn July 2023, EMBASE, PubMed, LILACS, and other databases were searched for articles reporting epidemiology, treatment, prenatal and perinatal outcomes, and patient journey of HDFN cases in Latin American countries. A snowball search of cross-references and gray literature complemented the initial search. Publications in English, Spanish, and Portuguese were reviewed. Data were extracted using a defined template and charted in tables.ResultsWe reviewed five guidelines and 19 observational studies from Brazil, Chile, Mexico, Argentina, Colombia, Panam & aacute;, Paraguay, and Peru. HDFN due to Rh alloimmunization ranged from 0.5 to 5 per 1000 live births, and anti-D remains the most frequent alloantibody type for severe HDFN. The perinatal mortality rate of HDFN is approximately 1.3-1.6 per 100,000 live births, and fetal deaths can reach 30% among patients treated with intrauterine transfusions. Up to 47% of alloimmunized pregnancies were referred to reference centers only during the third trimester. About 60% of eligible pregnancies received anti-D IgG prophylaxis.ConclusionsAlthough estimates in LATAM countries are scarce and lack standardized measures, we observed that the incidence, morbidity, and mortality of HDFN in this region are problematic. RhD alloimmunization was reported in approximately up to 70% of severe HDFN cases, despite anti D HDFN being largely preventable.
引用
收藏
页数：16
相关论文
共 55 条
  • [1] de Haas M., Thurik F.F., Koelewijn J.M., van der Schoot C.E., Haemolytic disease of the fetus and newborn, Vox Sang, 109, 2, pp. 99-113, (2015)
  • [2] Ree I.M.C., Smits-Wintjens V., van der Bom J.G., van Klink J.M.M., Oepkes D., Lopriore E., Neonatal management and outcome in alloimmune hemolytic disease, Expert Rev Hematol, 10, 7, pp. 607-616, (2017)
  • [3] de Winter D.P., Kaminski A., Tjoa M.L., Oepkes D., Hemolytic disease of the fetus and newborn: systematic literature review of the antenatal landscape, BMC Pregnancy Childbirth, 23, 1, (2023)
  • [4] Delaney M., Matthews D.C., Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn, Hematology, 2015, 1, pp. 146-151, (2015)
  • [5] De Winter D.P., Hulzebos C., Van 't Oever RM, De Haas M, Verweij EJ, Lopriore E: History and current standard of postnatal management in hemolytic disease of the fetus and newborn, Eur J Pediatr, 182, 2, pp. 489-500, (2023)
  • [6] Murray N.A., Roberts I.A., Haemolytic disease of the newborn, Arch Dis Child Fetal Neonatal Ed, 92, 2, pp. F83-F88, (2007)
  • [7] Hall V., Vadakekut E.S., Avulakunta I.D., Hemolytic Disease of the Fetus and Newborn, In: Statpearls. Treasure Island (FL): Statpearls Publishing, (2024)
  • [8] 192: Management of Alloimmunization During Pregnancy, Obstet Gynecol, 131, 3, pp. e82-e90, (2018)
  • [9] Dean L., Bethesda (MD): National Center for Biotechnology Information (US), Blood Groups and Red Cell Antigens, (2005)
  • [10] Bhutani V.K., Zipursky A., Blencowe H., Khanna R., Sgro M., Ebbesen F., Bell J., Mori R., Slusher T.M., Fahmy N., Et al., Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels, Pediatr Res, 74, pp. 86-100, (2013)
123456